ClinicalTrials.gg

Program

ranosidenib

Also written as “HMPL-306”, “HMPL-306 tablet” and “HMPL-306 Regimen”.

Its studies are mostly in Leukemia, Myeloid, Acute · Astrocytoma · Cholangiocarcinoma · Glioma, led by HUTCHMED.

Furthest: phase 3, since Apr 16, 20247 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED73 open or runningphase 3since Apr 16, 2024Feb 13, 2020Dec 2026phase 1 · NCT07025018

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2020First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04272957 · 75 enrolled · China
  2. Jan 19, 2021Phase 1 study in Leukemia, Myeloid, AcuteNCT04764474 · 46 enrolled · United States, Spain
  3. Feb 6, 2021Phase 1 study in CholangiocarcinomaNCT04762602 · 42 enrolled · United States, Spain
  4. Apr 16, 2024Phase 3 study in Leukemia, Myeloid, AcuteNCT06387069 · 316 planned · China
  5. Oct 29, 2024Phase 1 study in Mass Balance StudyNCT06671873 · 6 enrolled · China
  6. May 28, 2025Phase 1 study in GliomaNCT07025018 · 52 planned · China
  7. Oct 19, 2026Phase 3 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07912398 · 210 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in GliomaNCT07025018
  2. Dec 31, 2028Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT06387069
  3. Mar 2032Primary completion: phase 3 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07912398

TargetBeta

IDH1 →IDH2 →read by rule
“An orally bioavailable inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
vorasidenibruleAgios Pharmaceuticalsphase 312

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07912398Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation3Not yet recruitingMar 2032210
NCT07025018Glioma · China1RecruitingDec 202652
NCT06671873Mass Balance Study · China1CompletedFeb 28, 20256
NCT06387069Leukemia, Myeloid, Acute · China3RecruitingDec 31, 2028316
NCT04762602Cholangiocarcinoma · United States, Spain1TerminatedFeb 27, 202542
NCT04764474Leukemia, Myeloid, Acute · United States, Spain1TerminatedJan 15, 202546
NCT04272957Leukemia, Myeloid, Acute · China1UNKNOWNJun 30, 202175

How it is read

Names in the registry

  • “HMPL-306”, 4 entries
  • “HMPL-306 tablet”, 1 entry
  • “HMPL-306 Regimen”, 1 entry
  • “100 µCi [14C] HMPL-306”, 1 entry

Codes read as this program: HMPL306.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.